NEW ORLEANS--(BUSINESS WIRE)--B·R·A·H·M·S today announced positive results from the company’s BACH (Biomarkers in Acute Congestive Heart Failure) Multinational Study comparing its new blood test, MR-proADM (Mid-Regional pro-Adrenomedullin) to BNP (B-type Natriuretic Peptide) and NT-proBNP (N-Terminal pro-B-type Natriuretic Peptide), the current industry standard tests used in acute care settings worldwide, as a prognostic indicator in patients with heart failure. The results demonstrated that the MR-proADM test was accurate for prognosis of outcome of acute heart failure, quantitatively superior to both BNP and NT-proBNP. The data were presented by Prof. Stefan D. Anker, M.D., Ph.D., Department of Cardiology, Charité - Universitätsmedizin Berlin, at the American Heart Association’s (AHA) Scientific Sessions 2008 in New Orleans, LA. Early in 2008, MR-proADM was CE labeled and is currently marketed in the European Union.
